New study replicates association between genetic variation and antidepressant treatment response

July 16, 2008

Pharmacogenetics, the study of genetic variation that influences an individual's response to drugs, is an important and growing focus in all of medical research, including psychiatry. It is a complex field, however, revealed by the lack of consistent and replicable findings across multiple studies, but some encouraging results are beginning to emerge. A new study scheduled for publication in the June 15th issue of Biological Psychiatry evaluated genetic markers in the treatment response of antidepressants and this work implicates the same markers as found in a prior trial.

Lekman and colleagues, using clinical data and DNA samples from the largest depression treatment study to date, the STAR*D study, compared individual treatment response (the reduction or remission of depressive symptoms) to individual genotypes. The researchers found that certain markers, or variations, in the FKBP5 gene are associated with treatment response to citalopram, a widely used antidepressant drug. In other words, patients with a particular genotype tended to respond better to the antidepressant treatment than others. Silvia Paddock, Ph.D., corresponding author on this article, further explains: "Our results are encouraging, because they support earlier findings by a German group implicating the same gene. It is promising to see the same genetic markers to be associated with response in hospitalized patients in the German study, as well as non-hospitalized patients in our study."

John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, explains some background of this important gene: "FKBP5 is a gene that codes for a protein that influences the molecular actions of a class of stress hormones, the glucocorticoids. In prior studies, variation in this gene was associated with the emergence of dissociative symptoms in traumatized children and PTSD symptoms in adults who had been maltreated as children." Childhood maltreatment has been previously reported to be a predictor of poor response to some antidepressants. Now that this current report has also implicated variation in the FKBP5 gene as related to antidepressant response, he adds that "we now need to close this apparent 'loop,' i.e., we need to understand how, at a molecular level and in the context of the developing brain, FKBP5 links childhood maltreatment and antidepressant response." Dr. Paddock agrees that further research is necessary, noting that it's needed "in order to confirm our results in further samples and understand the mechanism by which the genetic markers influence the chance of a depressed patient to respond to an antidepressant. This will, ultimately, allow us to develop new and better treatment strategies."

Elsevier

---

---

	Coming of Age on Zoloft: How Antidepressants Cheered Us Up, Let Us Down, and Changed Who We Are by Katherine Sharpe (Author) When Katherine Sharpe arrived at her college health center with an age-old complaint, a bad case of homesickness, she received a thoroughly modern response: a twenty-minute appointment and a prescription for Zoloft—a drug she would take for the next ten years. This outcome, once unlikely, is now alarmingly common. Twenty-five years after Prozac entered the marketplace, 10 percent of Americans over the age of six use an SSRI antidepressant. In Coming of Age on Zoloft, Sharpe blends deeply personal writing, thoughtful interviews, and historical context to achieve an unprecedented portrait of the antidepressant generation. She explores questions of identity that arise for people who start medication before they have an adult sense of self. She asks why some individuals find a diagnosis of...
	The Antidepressant Solution: A Step-by-Step Guide to Safely Overcoming Antidepressant Withdrawal, Dependence, and "Addiction" by Joseph Glenmullen (Author) With the FDA's warning that antidepressants may cause agitation, anxiety, hostility, and even violent or suicidal tendencies, these medications are at the forefront of national legal news. Harvard physician Joseph Glenmullen has led the charge to warn the public that antidepressants are overprescribed, underregulated, and, especially, misunderstood in their side and withdrawal effects. Now he offers a solution! More than twenty million Americans -- including over one million teens and children -- take one of today's popular antidepressants, such as Paxil, Zoloft, or Effexor. Dr. Glenmullen recognizes the many benefits of antidepressants and prescribes them to his patients, but he is also committed to warning the public of the dangers associated with overprescription. Dr. Glenmullen's...
	The Essential Guide to Prescription Drugs, Update on Antidepressants, Focus on Lexapro (escitalopram) by The Medicine Information Institute Wondering when this medicine will start to go to work? Worried about possible side effects? Can drug interactions cloud the horizon? What help could herbal medicines be? The Essential Guide to Prescription Drugs helps answer all of these important questions, talks about how to tell if the medicine is starting to work and how to follow up if things seem to be going in the wrong direction. Includes cautions to take while you are on Lexapro, things to talk to youer doctor about before taking it and even tests and helpful web sites that may make things easier to understand.
	Taking Antidepressants: Your Comprehensive Guide to Starting, Staying On, and Safely Quitting by Michael Banov (Author) Antidepressants are the most commonly prescribed class of medications in this country ¬ 190 million prescriptions per year have been written since 2005. Yet, consumers have few available resources to educate them in a balanced fashion about starting and stopping antidepressants. People want to know if antidepressants are really safe, whether they are addictive, and how they may affect their personality. In this book, triple board-certified psychiatrist Dr. Michael Banov walks the reader through a personalized process to help them make the right choice about starting antidepressants, staying on antidepressants, and stopping antidepressants. He includes specific guidelines on how to safely reduce and ultimately stop taking antidepressants, if it is appropriate to do so. Readers will...
	The Anti-Depressant Fact Book: What Your Doctor Won't Tell You About Prozac, Zoloft, Paxil, Celexa, and Luvox by Peter R. Breggin (Author) Known as "the Ralph Nader of psychiatry," Dr. Peter Breggin has been the medical expert in countless court cases involving the use or misuse of psychoactive medications. This unusual position has given him unprecedented access to private pharmaceutical research and correspondence files, information from which informs this straight-talking guide to the most prescribed and controversial category of American drugs: antidepressants. From how these drugs work in the brain to how they treat (or don't treat) depression and obsessive-compulsive, panic, and other disorders; from the documented side and withdrawal effects to what every parent needs to know about antidepressants and teenagers, The Anti-Depressant Fact Book is up-to-the minute and easy-to-access. Hard-hitting and enlightening, every...
	The Antidepressant Era by David Healy (Author) When we stop at the pharmacy to pick up our Prozac, are we simply buying a drug? Or are we buying into a disease as well? The first complete account of the phenomenon of antidepressants, this authoritative, highly readable book relates how depression, a disease only recently deemed too rare to merit study, has become one of the most common disorders of our day--and a booming business to boot. The Antidepressant Era chronicles the history of psychopharmacology from its inception with the discovery of chlorpromazine in 1951 to current battles over whether these powerful chemical compounds should replace psychotherapy. An expert in both the history and the science of neurochemistry and psychopharmacology, David Healy offers a close-up perspective on early research and clinical trials,...
	The Antidepressant Antidote: Five Steps to Get Off Antidepressants Safely and Effectively by Bethany Butzer Ph.D. (Author) Do you want to get off antidepressants and move toward a more full and balanced life? Have you tried several times to get off antidepressants, only to end up right back on them? If so, this book is for you. In The Antidepressant Antidote: Five Steps to Get Off Antidepressants Safely and Effectively, Bethany Butzer, Ph.D. provides practical and proven techniques to help you get off antidepressants once and for all. This life-enhancing 5-step program will teach you: • How to get the support you need as you taper off antidepressants. • Tips to deal with the withdrawal effects that can arise when reducing your antidepressant dose. • Techniques to let go of stress, anxiety, sadness, and depression. • Smart choices to move you toward the type of life you...
	The Emperor's New Drugs: Exploding the Antidepressant Myth by Irving Kirsch Ph.D. (Author) Irving Kirsch has the world doubting the efficacy of antidepressants. Based on fifteen years of research, The Emperor's New Drugs makes an overwhelming case that what the medical community considered a cornerstone of psychiatric treatment is little more than a faulty consensus. But Kirsch does more than just criticize: He offers a path society can follow to stop popping pills and start proper treatment.
	ANTIDEPRESSANT DRUG INTERACTIONS IN THE ELDERLY: Understanding the P-450 system is half the battle in reducing risks (Postgraduate Medicine) by JTE Multimedia As patients age, pharmacologic treatment of depression becomes more complicated because of the increased risk of drug interactions in the elderly. Choosing an appropriate agent requires a thorough knowledge of cytochrome P-450 enzymes, which affect drug metabolism in the liver. In this article, Dr Cadieux explains the critical factors affecting antidepressant treatment in elderly patients and discusses potential and documented drug interactions of selected agents. Original Publication Date: November 1999
	The Prescriber's Guide: Antidepressants: Stahl's Essential Psychopharmacology by Stephen Stahl (Author), Meghan M. Grady (Editor), Nancy Munter (Editor) This spin-off from Stephen Stahl's new, completely revised, and fully updated fourth edition of the Prescriber's Guide covers the most important drugs in use today for treating depression. Now established as the indispensable formulary in psychopharmacology, easy to navigate and easy to use, the Prescriber's Guide combines evidence-based information with clinically-informed guidance to support clinicians in making the most effective prescribing decisions for the good of their patients. Incorporating information on the newest indications, new formulations, new recommendations and new safety data, this edition continues to provide the essential practical support required by anyone prescribing in the field of mental health.